vs
Akebia Therapeutics, Inc.（AKBA）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
RE/MAX Holdings, Inc.的季度营收约是Akebia Therapeutics, Inc.的1.2倍（$71.1M vs $57.6M），Akebia Therapeutics, Inc.同比增速更快（23.9% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $31.1M），过去两年Akebia Therapeutics, Inc.的营收复合增速更高（32.9% vs -4.7%）
Akebia Therapeutics是一家专注于肾病领域的生物制药企业，核心业务覆盖药物研发、临床试验及商业化推广全流程，主要开发针对慢性肾病相关贫血等适应症的创新疗法，面向全球市场，致力于满足肾病治疗领域未被满足的临床需求。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
AKBA vs RMAX — 直观对比
营收规模更大
RMAX
是对方的1.2倍
$57.6M
营收增速更快
AKBA
高出25.8%
-1.8%
自由现金流更多
RMAX
多$2.4M
$31.1M
两年增速更快
AKBA
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.6M | $71.1M |
| 净利润 | — | $1.4M |
| 毛利率 | 78.2% | — |
| 营业利润率 | -14.8% | 13.1% |
| 净利率 | — | 2.0% |
| 营收同比 | 23.9% | -1.8% |
| 净利润同比 | — | -75.2% |
| 每股收益（稀释后） | $-0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AKBARMAX
| Q4 25 | $57.6M | $71.1M | ||
| Q3 25 | $58.8M | $73.2M | ||
| Q2 25 | $62.5M | $72.8M | ||
| Q1 25 | $57.3M | $74.5M | ||
| Q4 24 | $46.5M | $72.5M | ||
| Q3 24 | $37.4M | $78.5M | ||
| Q2 24 | $43.6M | $78.5M | ||
| Q1 24 | $32.6M | $78.3M |
净利润AKBARMAX
| Q4 25 | — | $1.4M | ||
| Q3 25 | $540.0K | $4.0M | ||
| Q2 25 | $247.0K | $4.7M | ||
| Q1 25 | $6.1M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $-20.0M | $966.0K | ||
| Q2 24 | $-8.6M | $3.7M | ||
| Q1 24 | $-18.0M | $-3.4M |
毛利率AKBARMAX
| Q4 25 | 78.2% | — | ||
| Q3 25 | 84.0% | — | ||
| Q2 25 | 84.1% | — | ||
| Q1 25 | 86.7% | — | ||
| Q4 24 | 56.2% | — | ||
| Q3 24 | 62.2% | — | ||
| Q2 24 | 60.9% | — | ||
| Q1 24 | 64.4% | — |
营业利润率AKBARMAX
| Q4 25 | -14.8% | 13.1% | ||
| Q3 25 | 7.6% | 25.0% | ||
| Q2 25 | 22.6% | 19.3% | ||
| Q1 25 | 23.6% | 7.2% | ||
| Q4 24 | -30.8% | 5.9% | ||
| Q3 24 | -33.4% | 19.4% | ||
| Q2 24 | -20.0% | 20.6% | ||
| Q1 24 | -45.8% | 5.8% |
净利率AKBARMAX
| Q4 25 | — | 2.0% | ||
| Q3 25 | 0.9% | 5.4% | ||
| Q2 25 | 0.4% | 6.4% | ||
| Q1 25 | 10.7% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | -53.5% | 1.2% | ||
| Q2 24 | -19.7% | 4.7% | ||
| Q1 24 | -55.2% | -4.3% |
每股收益（稀释后）AKBARMAX
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $0.03 | — | ||
| Q4 24 | $-0.10 | — | ||
| Q3 24 | $-0.10 | — | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.09 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $184.8M | $118.7M |
| 总债务越低越好 | $48.3M | $432.2M |
| 股东权益账面价值 | $32.6M | $452.4M |
| 总资产 | $376.6M | $582.5M |
| 负债/权益比越低杠杆越低 | 1.48× | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资AKBARMAX
| Q4 25 | $184.8M | $118.7M | ||
| Q3 25 | $166.4M | $107.5M | ||
| Q2 25 | $137.3M | $94.3M | ||
| Q1 25 | $113.4M | $89.1M | ||
| Q4 24 | $51.9M | $96.6M | ||
| Q3 24 | $34.0M | $83.8M | ||
| Q2 24 | $39.5M | $66.1M | ||
| Q1 24 | $42.0M | $82.1M |
总债务AKBARMAX
| Q4 25 | $48.3M | $432.2M | ||
| Q3 25 | $47.6M | $433.3M | ||
| Q2 25 | $47.1M | $434.4M | ||
| Q1 25 | $46.5M | $435.3M | ||
| Q4 24 | $38.7M | $436.2M | ||
| Q3 24 | $38.4M | $437.2M | ||
| Q2 24 | $38.0M | $438.1M | ||
| Q1 24 | $30.1M | $439.0M |
股东权益AKBARMAX
| Q4 25 | $32.6M | $452.4M | ||
| Q3 25 | $41.6M | $448.1M | ||
| Q2 25 | $29.2M | $442.4M | ||
| Q1 25 | $24.6M | $433.5M | ||
| Q4 24 | $-49.2M | $429.5M | ||
| Q3 24 | $-50.4M | $423.1M | ||
| Q2 24 | $-33.8M | $418.4M | ||
| Q1 24 | $-27.3M | $412.0M |
总资产AKBARMAX
| Q4 25 | $376.6M | $582.5M | ||
| Q3 25 | $364.2M | $582.2M | ||
| Q2 25 | $345.6M | $574.8M | ||
| Q1 25 | $310.2M | $571.4M | ||
| Q4 24 | $220.7M | $581.6M | ||
| Q3 24 | $207.1M | $578.6M | ||
| Q2 24 | $220.2M | $571.4M | ||
| Q1 24 | $225.5M | $566.7M |
负债/权益比AKBARMAX
| Q4 25 | 1.48× | 0.96× | ||
| Q3 25 | 1.15× | 0.97× | ||
| Q2 25 | 1.61× | 0.98× | ||
| Q1 25 | 1.89× | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $31.1M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $31.1M | $33.5M |
| 自由现金流率自由现金流/营收 | 53.9% | 47.1% |
| 资本支出强度资本支出/营收 | 0.1% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $67.7M | $56.8M |
8季度趋势，按日历期对齐
经营现金流AKBARMAX
| Q4 25 | $31.1M | $40.9M | ||
| Q3 25 | $28.1M | $17.7M | ||
| Q2 25 | $22.3M | $4.6M | ||
| Q1 25 | $-13.6M | $5.7M | ||
| Q4 24 | $-4.5M | $59.7M | ||
| Q3 24 | $-6.7M | $17.6M | ||
| Q2 24 | $-10.1M | $15.9M | ||
| Q1 24 | $-19.4M | $9.4M |
自由现金流AKBARMAX
| Q4 25 | $31.1M | $33.5M | ||
| Q3 25 | $28.0M | $16.4M | ||
| Q2 25 | $22.2M | $2.9M | ||
| Q1 25 | $-13.6M | $4.0M | ||
| Q4 24 | $-4.5M | $53.0M | ||
| Q3 24 | $-6.7M | $16.3M | ||
| Q2 24 | $-10.1M | $14.0M | ||
| Q1 24 | — | $6.8M |
自由现金流率AKBARMAX
| Q4 25 | 53.9% | 47.1% | ||
| Q3 25 | 47.7% | 22.4% | ||
| Q2 25 | 35.6% | 4.0% | ||
| Q1 25 | -23.7% | 5.3% | ||
| Q4 24 | -9.6% | 73.2% | ||
| Q3 24 | -17.9% | 20.8% | ||
| Q2 24 | -23.1% | 17.8% | ||
| Q1 24 | — | 8.6% |
资本支出强度AKBARMAX
| Q4 25 | 0.1% | 10.4% | ||
| Q3 25 | 0.1% | 1.8% | ||
| Q2 25 | 0.2% | 2.2% | ||
| Q1 25 | 0.0% | 2.3% | ||
| Q4 24 | 0.0% | 9.1% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.1% | 2.4% | ||
| Q1 24 | 0.0% | 3.3% |
现金转化率AKBARMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | 52.05× | 4.45× | ||
| Q2 25 | 90.47× | 0.97× | ||
| Q1 25 | -2.22× | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AKBA
| Auryxia | $48.1M | 84% |
| Vafseo | $6.2M | 11% |
| License Collaboration And Other Revenue | $3.3M | 6% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
